Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mercadal, L.
Right arrow Articles by Martinez, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mercadal, L.
Right arrow Articles by Martinez, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 1771-1778
© 2002 European Renal Association-European Dialysis and Transplant Association

Factors affecting outcome and prognosis in membranous lupus nephropathy

Lucile Mercadal1,, Sophie Tézenas du Montcel4, Dominique Nochy5, Guillaume Queffeulou2, Jean-Charles Piette6, Corinne Isnard-Bagnis1 and Frank Martinez3 and the Groupe d'Etudes Néphrologiques en Ile de France

1 Nephrology Department, Pitié Salpêtrière Hospital, 2 Nephrology Department, Bichat Hospital and 3 Nephrology Department Saint Louis Hospital, 4 Biostatistic Department, Pitié Salpêtrière Hospital, 5 Pathology Department, Georges Pompidou European Hospital and 6 Internal Medicine Department, Pitié Salpétriêre Hospital, Paris, France

Background. This study was designed to review the prognosis and the predictors of renal outcome in patients with membranous lupus nephropathy (MLN) with no or mild mesangial proliferation.

Methods. The medical records of patients (n=66) with biopsy-proven MLN, WHO class VA, and class VB without any past history of proliferative lupus nephropathy (PLN) were reviewed retrospectively.

Results. The mean follow-up was 6.9±0.2 years and renal survival at 5 and 10 years was 97±2 and 88±6%. Twenty-nine patients underwent a second renal biopsy during follow-up. Fourteen of these patients (21%) had lesions of PLN. Among them, four reached end-stage renal disease (ESRD) despite immunosuppressive treatment. The probability of a transition from MLN to PLN at 10 years was 35±8%. Two other patients reached ESRD but did not have repeat renal biopsies and two had biopsy-proven progression to fibrosis. Independent risk factors associated with the doubling of creatinine were transition into PLN and the occurrence of a thrombosis during follow-up. The only predictor of ESRD was the haemoglobin level. PLN was not a predictor of ESRD but the efficient treatment of this form of lupus nephritis prevented that outcome.

Conclusions. With a long follow-up, our study noted a high frequency of transition into PLN in a large cohort of patients with MLN. Steroid usage was not predictive of outcome and did not affect renal survival, a result that must be qualified in light of the highly variable duration of treatments with steroids. The early screening and treatment of PLN is the main benefit of the close follow-up of patients with MLN. Progression to ESRD with only fibrosis remains a rare event.

Keywords: lupus nephritis; membranous lupus nephropathy

Correspondence and offprint requests to: L. Mercadal, Hôpital Pitié Salpétrière, Service de Néphrologie, 83 Boulevard de l'hôpital, F-75013 Paris, France. Email: lucile.mercadal{at}psl.ap\|[hyphen]\|hop\|[hyphen]\|paris.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
C. Mok, K. Ying, C. Yim, W. Ng, and W. Wong
Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine
Lupus, October 1, 2009; 18(12): 1091 - 1095.
[Abstract] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
L. H. Beck Jr. and D. J. Salant
Treatment of Membranous Lupus Nephritis: Where Are We Now?
J. Am. Soc. Nephrol., April 1, 2009; 20(4): 690 - 691.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
H. A. Austin III, G. G. Illei, M. J. Braun, and J. E. Balow
Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy
J. Am. Soc. Nephrol., April 1, 2009; 20(4): 901 - 911.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C.-C. Wu, K.-C. Lu, J.-S. Chen, H.-Y. Hsieh, S.-H. Lin, P. Chu, J.-Y. Wang, H.-K. Sytwu, and Y.-F. Lin
HO-1 induction ameliorates experimental murine membranous nephropathy: anti-oxidative, anti-apoptotic and immunomodulatory effects
Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3082 - 3090.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
H.O. Sun, W.X. Hu, H.L. Xie, H.T. Zhang, H.P. Chen, C.H. Zeng, Z.H. Liu, and L.S. Li
Long-term outcome of Chinese patients with membranous lupus nephropathy
Lupus, January 1, 2008; 17(1): 56 - 61.
[Abstract] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. H. Cramer II, M. Mills, R. P. Valentini, W. E. Smoyer, H. Haftel, and P. D. Brophy
Clinical presentation and outcome in a cohort of paediatric patients with membranous lupus nephritis
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3495 - 3500.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
H A Austin and G G Illei
Membranous lupus nephritis
Lupus, January 1, 2005; 14(1): 65 - 71.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.